Yoshihiro Tadori
6PUBLICATIONS
0CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|May 19, 2018
Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan.Hideo Matsumoto, Jun Ishigooka, Hiroaki Ono
|May 19, 2018
Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study.Jun Ishigooka, Shuichi Iwashita, Yoshihiro Tadori
|Apr 17, 2018
Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder.Kunitoshi Kamijima, Mahito Kimura, Kazuo Kuwahara
|Mar 28, 2018
Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study.Jun Ishigooka, Shuichi Iwashita, Yoshihiro Tadori
|Sep 24, 2017
An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan.Hironobu Ichikawa, Michio Hiratani, Akihiro Yasuhara
|Dec 23, 2016
Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study.Hironobu Ichikawa, Katsunaka Mikami, Takashi Okada
Pageof 1
